Hemostemix (OTCQB: HMTXF) closed the second tranche of its previously announced non-brokered private placement, raising aggregate gross proceeds of CDN$322,250 through the issuance of 6,445,000 units at CDN$0.05 per unit. Each unit includes one common share and one-half warrant; each whole warrant is exercisable at CDN$0.12 for 24 months, subject to an acceleration clause if the share price meets specified TSXV trading thresholds.
Hemostemix paid approximately CDN$21,780 in cash finder’s fees and issued 435,600 finder warrants exercisable at CDN$0.06 for 24 months. Proceeds are expected to fund sales, marketing, patient acquisition, physician education, ACP-01 production, Bahamian regulatory filings, and working capital. The TSXV extended the deadline to close the remaining CDN$1,000,000 of the placement to August 14, 2026, and the offering remains subject to final Exchange acceptance, with all securities under a four‑month‑plus‑one‑day hold.
Loading...
Loading translation...
Positive
Second tranche financing closed CDN$322,250 raised via 6,445,000 units at CDN$0.05
Additional capital access TSXV extended deadline to close remaining CDN$1,000,000 to August 14, 2026
Proceeds allocated to ACP-01 commercialization, Bahamian regulatory filings, and working capital
Warrants issued potential future proceeds at CDN$0.12 and CDN$0.06 over 24 months
Negative
Equity dilution 6,445,000 new shares plus unit and finder warrants issued
Regulatory condition financing remains subject to final TSXV acceptance
Restricted liquidity all securities subject to four months plus one day hold period
Calgary, Alberta--(Newsfile Corp. - July 30, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the second tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026. The Company raised aggregate gross proceeds of CDN$322,250 under the second tranche through the issuance of 6,445,000 units ("Units") at a price of CDN$0.05 per
Unit.Each Unit consists of one common share in the capital of the Company (a "Common Share") and one-half of one common share purchase warrant (a "Warrant"). Each whole Warrant entitles the holder to acquire one additional Common Share at a price of CDN$0.12 per share for a period of 24 months from the closing date of the second tranche of the Offering, subject to the accelerated expiry provision described below. If, during any 10 consecutive trading days occurring after four months and one day has elapsed following the closing date of the Offering, the volume-weighted average trading price of the Common Shares (or the closing bid, if no sales were reported on a trading day) as quoted on the TSX Venture Exchange ("Exchange") is greater than or equal to CDN$0.15 per Common Share, the Company may accelerate the expiry date of the Warrants to the date that is 30 days following the date on which the Company issues a news release announcing the acceleration.
In connection with the second tranche of the Offering, the Company paid eligible finders aggregate cash finder's fees of approximately CDN$21,780 and issued 435,600 finder warrants (the "Finder Warrants"). Each Finder Warrant entitles the holder to purchase one Common Share at an exercise price of CDN$0.06 per share for a period of 24 months from the closing date of the second tranche.
The proceeds of the Offering are expected to be used for, sales, marketing, patient acquisition, physician education, and commercialization initiatives; production and manufacturing expenses associated with ACP-01 treatments; regulatory and filing fees associated with submissions to the Ministry of Health and Wellness of the Commonwealth of The Bahamas; and general working capital and corporate purposes.
The Offering remains subject to final acceptance by the Exchange. All securities issued in connection with the second tranche of the Offering are subject to a statutory hold period of four months plus one day from the closing date in accordance with applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.
The TSXV has granted the Company an extension to August 14, 2026, to close the balance of the non brokered private placement of $1,000,000.
About Hemostemix
Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ an investigational autologous stem cell therapy developed to support circulation in areas affected by diseases of ischemia. VesCell™ is derived from a patient's own blood and evaluated through structured clinical research. Hemostemix has completed seven clinical studies of 318 subjects and published its results in eleven peer reviewed publications. ACP-01 is safe, and appears clinically relevant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI diabetes-based patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com.
For further information, please contact:Thomas Smeenk, President and CEO, EM: tsmeenk@hemostemix.com , PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to, but is not limited to, the non brokered private placement of $1,000,000. Forward-looking information is based on assumptions and involves known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking information, including the risk that the restatement process and adjustments may change, or that the non-brokered private placement may not close. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"), if any; the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
What are the key terms of Hemostemix (HMTXF) private placement closed on July 30, 2026?
Hemostemix closed the second tranche raising CDN$322,250 by issuing 6,445,000 units at CDN$0.05 per unit. According to Hemostemix, each unit includes one common share and one-half warrant exercisable at CDN$0.12 for 24 months, with an acceleration feature.
How many units did Hemostemix (HMTXF) issue and how much was raised in the second tranche?
Hemostemix issued 6,445,000 units and raised gross proceeds of CDN$322,250 in the second tranche. According to Hemostemix, the units were priced at CDN$0.05 each and included shares and warrants that may generate additional capital if exercised.
How will Hemostemix (HMTXF) use the proceeds from its July 2026 private placement?
Hemostemix expects to use proceeds for sales, marketing, patient acquisition, physician education, and commercialization initiatives. According to Hemostemix, funds will also support ACP-01 production, Bahamian regulatory and filing fees, and general working capital and corporate purposes linked to its stem cell therapy platform.
What is the TSXV extension to August 14, 2026 for Hemostemix (HMTXF)?
The TSXV granted Hemostemix an extension to August 14, 2026 to close the balance of its CDN$1,000,000 non-brokered private placement. According to Hemostemix, this extension applies to the remaining portion beyond the second tranche already closed.
What are the warrant terms in Hemostemix (HMTXF) July 2026 private placement?
Each whole unit warrant allows purchase of one share at CDN$0.12 for 24 months, with an acceleration clause tied to TSXV trading prices. According to Hemostemix, finder warrants are exercisable at CDN$0.06 for 24 months from the second tranche closing date.
How might the July 2026 private placement affect Hemostemix (HMTXF) shareholders?
The placement increases outstanding shares by 6,445,000 and adds warrants, creating potential dilution for existing shareholders. According to Hemostemix, proceeds are earmarked for commercialization, regulatory efforts, and working capital, which could support operations but expand the equity base.
Are the new Hemostemix (HMTXF) securities from the second tranche freely tradable?
No, all securities issued in the second tranche are subject to a statutory hold of four months plus one day. According to Hemostemix, additional jurisdictional restrictions may also apply, and the offering still requires final acceptance from the TSX Venture Exchange.
